Nautilus Biotechnology, Inc. (NAUT)
After hours:
| Previous close | 2.5600 |
| Open | 2.5900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 2.4100 - 2.6150 |
| 52-week range | 2.3000 - 4.4200 |
| Volume | |
| Avg. volume | 65,283 |
| Market cap | 301.889M |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.5400 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.58 |
GlobeNewswireNautilus Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
SEATTLE, May 23, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Goldman Sachs 45th Annual Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, June 10, 2024, at 8:40 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section
Simply Wall St.We're Hopeful That Nautilus Biotechnology (NASDAQ:NAUT) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GuruFocus.com
Nautilus Biotechnology Inc (NAUT) Q1 2024 Earnings Call Transcript Highlights: A Detailed ...
Explore key financial outcomes and strategic insights from Nautilus Biotechnology's first quarter of 2024, emphasizing growth in expenses and future expectations.
